http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Pembrolizumab 투여로 Pseudoprogression 이후 완전 관해에 도달한 호지킨 림프종 1예
홍주현 ( Joohyun Hong ),배주환 ( Joohwan Bae ),이상글 ( Sang Geul Lee ),임민기 ( Mingi Lim ),고영혜 ( Young Hye Ko ),김석진 ( Seok Jin Kim ),김원석 ( Won Seog Kim ) 대한내과학회 2017 대한내과학회지 Vol.92 No.4
Classical Hodgkin lymphoma (cHL) is a highly curable disease, but the prognosis for relapsed/refractory cHL is grave. Pembrolizumab has recently shown impressive effects in patients with relapsed/refractory cHL in a phase Ib study (KEYNOTE-013). This report presents a case of a 17-year-old male with refractory cHL who received multiple chemotherapy regi-mens and radiotherapies, including brentuximab vedotin. Following both the second and fourth cycles of intravenous pem-brolizumab 100 mg (2 mg/kg), positron emission tomography/computed tomography (PET/CT) scan showed progression. However, because performance status and fever improved, treatment was continued, and complete remission was confirmed by PET/CT after eight cycles of pembrolizumab. This case suggests that clinicians need to be aware of the potential for pseudoprog-ression in patients treated with pembrolizumab. (Korean J Med 2017;92:415-418)